



DONCASTER & BASSETLAW AREA PRESCRIBING COMMITTEE (APC) Action Notes and Log

Thursday 24th October 2019 12 Noon start **Meeting Room 3 Sovereign House**

Present: Dr David Crichton

r David Crichton Chair, APC Chair DCCG

Mrs V-Lin Cheong Deputy Head of Medicines Management DCCG

Mr Rob Wise Head of Medicines Management BCCG, Deputy APC Chair

Dr Rachel Hubbard Doncaster GP

Mr Stephen Davies Chief Pharmacist RDaSHFT

Dr Rumit Shah Local Medical Committee Representative

Mr Lee Wilson Consultant Pharmacist DBTHFT

Dr Lucy Peart Acute Physician DBTHFT

Miss Faiza Ali Practice Support Pharmacist DCCG (standing in as secretary)

In attendance: Mr David Smith

Miss Holly Smith

Data Quality and Performance Improvement/Service Manager RDaSHFT

Pre-registration Pharmacist

Minutes only: Dr Rupert Suckling &

Dr Victor Joseph

DMBC Representatives

Agenda Ref	Subject / Action Required	Action Required By	Timescale	Status of Action (RAG) and Date
10/19/1	Apologies for Absence: Alex Molyneux, Munashe Mvududu, Paula Whitehurst The Chair welcomed Dr Hubbard to her first APC meeting.			
10/19/2	Declarations of Interest: Dr Shah declared that from next year his will be a governor on the Acute Trust board in Rotherham			
10/19/2.1	Fire Alarm Procedure: No test planned			
10/19/2.2	Notification of Any Other Business: None			
10/19/3	Notes of the Meeting Held On: Thursday 26th Sept 2019 were agreed as a true and accurate record and will be made available on the Medicines Management website.			
10/19/4	Matters Arising not on the Agenda: PREVENT Programme - Discussion around the use of combined oral contraception in females of child bearing age who are taking Sodium Valproate. It was emphasised that long acting contraception is first line and if a patient chooses to opt for oral contraception a higher dose may be required and this should be discussed between the GP and the patient and a declaration form should be signed and clearly documented. Antibiotic Guidelines - These are near to being finalised, NICE guidance on Community Acquired Pneumonia has just been released and this is currently being discussed with the microbiologists at DBTHFT to ensure they agree that the document concurs.			
10/19/4.1	Matters Arising			
01/19/8.10	Dementia SCP SD discussed the bullet points added in to the document. MOCA tool used to assess severity was discussed and it was suggested that the same scale should be used to assess all patients for consistency. Memantine was discussed and the TLS status of this was reviewed from Amber to Green G in line with recent NICE guidance that supports GP's initiating, if confident to do so, otherwise patients can still be referred in to the mental health team where appropriate. The SCP references are to be removed as this will be 'guidance' going forward. The date approved can be moved to Oct 19 and the document was agreed subject to	RDaSHFT-SD	Oct 19	

	the minor suggested changes.			
04/19/19.1	Shared Care Pathway for Antipsychotics The date agreed for SMI health checks is the 16 th of Dec 2019. The SMI service recruitment is complete. It was discussed as to whether the RDASH SMI pharmacist would review all patient meds or just antipsychotics and it was confirmed that it would be just antipsychotics. RS raised that the biggest concern is how someone would be referred back if the patient went into a crisis post discharge however there are opportunities for patients to be reviewed by services as part of the specification. It was discussed that appropriate read coding to identify patients on the SMI register is key to correct identification. The committee discussed the differences between patients falling under the SMI register or not. DC highlighted that there are currently additional discussions nationally regarding borderline personality disorder but the current guidance does not cover this cohort of patients at present. It was agreed that antipsychotic prescribing for patients who fall under the SMI register would be classified on the TLS as Amber G whilst the non SMI register patients (BPD and LD) would remain as present. The document contents were agreed by the committee RS suggested that it would be useful to share the document at the next LMC meeting.	RDaSHFT-SD	Nov 19	
05/19/8.3	Melatonin SCP In the shared care document there are two brands not listed that are indicated for a particular cohort of children and so these need to be added to the shared care document. LW agreed to make the amendments. The table on page one is to be extended to include Slenyto brand. There was a discussion about whether melatonin liquid form is required. DBTHFH will bring the updated shared care protocol back.	DBTHFT-LW	Jan 20	
09/19/8.5	Tadalafil It was agreed that once daily dosed tadalafil should be given a Grey TLS status. Due to the long half-life of tadalafil the higher dose twice weekly is just as effective. Tadalafil daily is in the national list of drugs that should not be routinely prescribed in primary care. 2.5mg and 5mg tadalafil will be separated from the 10mg and 20mg PRN dose strengths that are Green-G and will be given a Grey 5 status.	NHSB-RW		

10/19/5	Drugs for Review	DCCG-VLC		
	None.	DCCG-VLC		
10/19/6	Officers Actions All officers' actions were agreed as proposed and will be updated on the traffic light system.	DCCG-VLC		
10/19/7	Drugs for Consideration Antacid & Oxetacaine (all brands) used post radiotherapy has been classified as Amber G	DCCG-VLC		
	Botulinum toxin type A (Xeomin) used for chronic sialorrhoea caused by neurological conditions in adults has been classified as Red 1,2			
	Larotrectinib (Vitrakvi) used for solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion has been classified as Grey 2			
	Neratinib (Nerlynx) used for early-stage hormone receptor positive HER2- overexpressed/amplified breast cancer who have completed adjuvant trastuzumab-based therapy <1 year ago has been classified as Red 1,2			
10/19/8	New Business			
10/19/8.1	Cleen Enemas A prescription request has come from Sheffield Children's hospital to a local GP practice, The SPC is licensed indication for occasional constipation. It was agreed that this should be Amber G for the indication of occasional constipation. The other indication of large volume bowel cleansing (Fleet) is to be left as Red on the TLS. VLC agreed to let the practice know the decision taken today.	DCCG-VLC		
10/19/9	DBTHFT D&TC Update The minutes of the meeting held in Sept 2019 and Oct 2019 were received by the Committee.			
10/19/10	Formulary Liaison Group Update The minutes of the meeting held in Sept 2019 were received by the Committee.			
10/19/11	Doncaster Prisons Drug & Therapeutic Committee update No minutes available			
10/19/12	RDaSH FT Medicines Management Committee update No minutes available			
10/19/13	Barnsley Area Prescribing Committee Update			

	The minutes of the meeting held in Aug 2019 and Sept 2019 were received by the Committee.			
10/19/14	Rotherham Medicines Optimisation Group Update No minutes available			
10/19/15	Sheffield Area Prescribing Committee Update The minutes of the meeting held in Sept 2019 were received by the Committee.			
10/19/16	Nottingham Area Prescribing Committee Update The minutes of the meeting held in July 2019 were received by the Committee.			
10/19/17	SY& B ICS Medicines Optimisation Work-stream Steering Group The minutes of the meeting held in July 2019 were received by the Committee.			
10/19/18	Northern Regional Medicines Optimisation Committee No minutes available.			
10/19/19	Any Other Business:			
10/19/8.4	Memantine National Shortage SD raised this and informed the committee that this should be resolved by the end of Nov 19. The advice to prolong stock is for prescribers to prescribe patients an altertnative strength dose; half a tablet daily or one tablet on alternate days instead of one tablet daily to bridge the supply gap. This applies to all strengths.			
10/19/8.5	ICS OTC launch The ICS 'over the counter' campaign launch should be imminent. Videos will be uploaded onto waiting room screens and it will be hopefully taken forward into A&E departments also. It will have an online presence and be incorporated into social media and websites.			
10/19/19.1	Date and Time of Next Meeting: 12 noon prompt Thursday 28th November 2019 Meeting Room 3 Sovereign House			

KEY

· -		
Completed / Closed	To Action	
In Progress	To be actioned but date not yet due	